Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NYSE | Common Stock
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company operates through Prevention and Recovery, and Reconstructive segments.
Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
The company distributes its products through independent distributors and directly under the ESAB and DJO brands.
Enovis Corporation was formerly known as Colfax Corporation.
The company was founded in 1995 and is headquartered in Wilmington, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | 0.73 Increased by +30.36% | 0.62 Increased by +17.74% |
| Aug 7, 24 | 0.62 Increased by +1.64% | 0.59 Increased by +5.08% |
| May 2, 24 | 0.50 Increased by +13.64% | 0.48 Increased by +4.17% |
| Feb 22, 24 | 0.79 Increased by +9.72% | 0.74 Increased by +6.76% |
| Nov 7, 23 | 0.56 Decreased by -5.08% | 0.54 Increased by +3.70% |
| Aug 3, 23 | 0.61 Increased by +3.39% | 0.52 Increased by +17.31% |
| May 4, 23 | 0.44 Increased by +18.92% | 0.37 Increased by +18.92% |
| Feb 23, 23 | 0.72 Decreased by -59.32% | 0.66 Increased by +9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 505.22 M Increased by +21.00% | -31.52 M Decreased by -994.48% | Decreased by -6.24% Decreased by -804.50% |
| Jun 30, 24 | 525.16 M Increased by +22.56% | -18.64 M Decreased by -86.47% | Decreased by -3.55% Decreased by -52.15% |
| Mar 31, 24 | 516.27 M Increased by +27.11% | -72.00 M Decreased by -215.14% | Decreased by -13.95% Decreased by -147.93% |
| Dec 31, 23 | 455.02 M Increased by +11.33% | 2.96 M Increased by +105.41% | Increased by +0.65% Increased by +104.86% |
| Sep 30, 23 | 417.52 M Increased by +8.78% | -2.88 M Increased by +95.63% | Decreased by -0.69% Increased by +95.99% |
| Jun 30, 23 | 428.50 M Increased by +8.45% | -9.99 M Decreased by -108.28% | Decreased by -2.33% Decreased by -107.64% |
| Mar 31, 23 | 406.15 M Decreased by -60.31% | -22.85 M Decreased by -251.62% | Decreased by -5.63% Decreased by -482.03% |
| Dec 31, 22 | 408.71 M Decreased by -60.06% | -54.84 M Decreased by -2.78 K% | Decreased by -13.42% Decreased by -7.10 K% |